Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Tan, Jing  [Clear All Filters]
Journal Article
Chen J, Zuo Z, Gao Y, Yao X, Guan P, Wang Y, Li Z, Liu Z, Hong JHan, Deng P, et al. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. Clin Epigenetics. 2023;15(1):19.
Meng M-Y, Li L, Wang W-J, Liu F-F, Song J, Yang S-L, Tan J, Gao H, Zhao Y-Y, Tang W-W, et al. Assessment of tumor promoting effects of amniotic and umbilical cord mesenchymal stem cells in vitro and in vivo. J Cancer Res Clin Oncol. 2019.
Tan J, Tan P, Teh BTean. Defining the Molecular Alterations of Ampullary Carcinoma. Cancer Cell. 2016;29(2):135-136.
Liu W, Zhang P, Tan J, Lin Y. Differentiation of Urine-Derived Induced Pluripotent Stem Cells to Neurons, Astrocytes, and Microvascular Endothelial Cells from a Diabetic Patient. Cell Reprogram. 2020.
Wang X, Cai S, Tang S, Yang L, Tan J, Sun X, Gong F. Effect of lifestyle or metformin interventions before IVF/ICSI treatment on infertile women with overweight/obese and insulin resistance: a factorial design randomised controlled pilot trial. Pilot Feasibility Stud. 2023;9(1):160.
Rui Q, Tan J, Jin J, Ye W, Zhou Y, Chen J. Establishment of a PBMC-derived induced pluripotent stem cell (NJUCMi001-A) from a patient with LAMA2-related congenital muscular dystrophy (MDC1A) carrying frameshift deletion c.3367delA in LAMA2 gene. Stem Cell Res. 2022;65:102957.
Lim WKhong, Ong CKiat, Tan J, Thike AAye, Ng CChuan Youn, Rajasegaran V, Myint SSwe, Nagarajan S, Nasir NDiyana Md, McPherson JR, et al. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014.
Chen J, Hong JHan, Huang Y, Liu S, Yin J, Deng P, Sun Y, Yu Z, Zeng X, Xiao R, et al. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023;22(1):85.
Xing M, Ooi WFong, Tan J, Qamra A, Lee P-H, Li Z, Xu C, Padmanabhan N, Lim JQuan, Guo YAmanda, et al. Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. J Clin Invest. 2020.
Tan J, Ong CKiat, Lim WKhong, Ng CChuan Youn, Thike AAye, Ng LMoy, Rajasegaran V, Myint SSwe, Nagarajan S, Thangaraju S, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015.
Hong JHan, Yong CHan, Heng HLee, Chan JYongsheng, Lau MChan, Chen J, Lee JYi, Lim AHerbert, Li Z, Guan P, et al. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies. Gut. 2023.
Cai W, Tan J, Yan J, Zhang L, Cai X, Wang H, Liu F, Ye M, Cai C-L. Limited Regeneration Potential with Minimal Epicardial Progenitor Conversions in the Neonatal Mouse Heart after Injury. Cell Rep. 2019;28(1):190-201.e3.
Li X-H, Wang H-P, Tan J, di Wu Y-, Yang M, Mao C-Z, Gao S-F, Li H, Chen H, Bin Cai W-. Loss of pigment epithelium-derived factor leads to ovarian oxidative damage accompanied by diminished ovarian reserve in mice. Life Sci. 2018.
Chen T, Ye B, Tan J, Yang H, He F, Khalil RA. Mesenchymal stem cells treatment improves vascularization, muscle contraction and VEGF expression, and reduces apoptosis in rat ischemic hind limb. Biochem Pharmacol. 2021:114530.
Yu Z, Deng P, Chen Y, Lin D, Liu S, Hong J, Guan P, Chen J, Zhong M-E, Chen J, et al. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer. Proc Natl Acad Sci U S A. 2024;121(6):e2304619121.
Wang Y, Zhou W, Chen J, Chen J, Deng P, Chen H, Sun Y, Yu Z, Pang D, Liu L, et al. Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma. MedComm (2020). 2023;4(4):e284.
Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, Liu L, Yu Z, Huang Y, Xiong Z, et al. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022.
Liu S, Zou Q, Chen J-P, Yao X, Guan P, Liang W, Deng P, Lai X, Yin J, Chen J, et al. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. J Clin Invest. 2021.
Lai J, Yang S, Lin Z, Huang W, Li X, Li R, Tan J, Wang W. Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies. Am J Clin Oncol. 2023.